Saturday, February 27, 2021
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Events
    • All Events
    • Deadlines
    • Webinar-Webcast
    • Awareness Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Events
    • All Events
    • Deadlines
    • Webinar-Webcast
    • Awareness Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biodetection

BARDA and JPEO-CBRND Back Cepheid’s Multiplex Test for Influenza, SARS-CoV2 and RSV

by Global Biodefense Staff
October 8, 2020
BARDA and JPEO-CBRND Back Cepheid’s Multiplex Test for Influenza, SARS-CoV2 and RSV

During the upcoming flu season, public health and medical professionals will require diagnostic tools to determine if a patient with fever and respiratory symptoms has COVID-19 or influenza, to better enable proper patient management and treatment.

A single test intended to detect COVID-19, influenza and respiratory syncytial virus (RSV) will receive advanced development support through a new collaboration between the Biomedical Advanced Research and Development Authority (BARDA), the U.S. Department of Defense’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), the U.S. Army Medical Materiel Development Activity (USAMMDA), and Cepheid, Inc., of Sunnyvale, California.

Cepheid’s Xpert Xpress SARS-CoV-2/Flu/RSV test is being designed to provide rapid, qualitative detection of SARS-CoV-2, Influenza A, Influenza B, and RSV; as well as distinguish between these diseases in a single-patient sample. The test will operate on Cepheid’s GeneXpert systems, in both laboratory and point-of-care settings.

“Things may get complicated this respiratory season as clinicians encounter a range of viral infections with symptoms overlapping with COVID-19, including Flu A, Flu B, and respiratory syncytial virus,” said Dr. David Persing, MD, Ph.D., Chief Medical and Technology Officer at Cepheid. “The ability to run a single, highly sensitive test that detects all four viruses in a syndromic panel provides actionable results and helps to alleviate pressure on our healthcare system.”

Development of the test will leverage Cepheid’s FDA-cleared Xpert Xpress Flu/RSV test and their Xpert Xpress SARS-CoV-2 test; the latter developed through a partnership between the BARDA, the JPEO-CBRND, and Cepheid, Inc. and granted EUA by the FDA on March 20, 2020.

An Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) was granted to the company at the end of September.

Tags: AwardsBARDACOVID-19Editor PickInfluenzaJPEO-CBRNDPOC DiagnosticsRapid DiagnosticsRSVSARS-CoV-2

Related Posts

First Human Trial of COVID-19 Vaccine Finds it is Safe and Induces Rapid Immune Response
Historical Reflections

COVID-19 Vaccination: What We Can Learn From the Great Polio Vaccine Heist of 1959

February 24, 2021
Sign on street in Conakry that says Ebola in large letters
Biosecurity

Why Ebola is Back in Guinea and Why the Response Must Be Different This Time

February 24, 2021
How Roald Dahl Became a Passionate Vaccine Advocate
Historical Reflections

How Roald Dahl Became a Passionate Vaccine Advocate

February 23, 2021
How Do We Know the COVID Vaccine Won’t Have Long-Term Side-Effects?
Infectious Diseases

How Do We Know the COVID Vaccine Won’t Have Long-Term Side-Effects?

February 23, 2021
Load More

Latest News

First Human Trial of COVID-19 Vaccine Finds it is Safe and Induces Rapid Immune Response

COVID-19 Vaccination: What We Can Learn From the Great Polio Vaccine Heist of 1959

February 24, 2021
Sign on street in Conakry that says Ebola in large letters

Why Ebola is Back in Guinea and Why the Response Must Be Different This Time

February 24, 2021
How Roald Dahl Became a Passionate Vaccine Advocate

How Roald Dahl Became a Passionate Vaccine Advocate

February 23, 2021
How Do We Know the COVID Vaccine Won’t Have Long-Term Side-Effects?

How Do We Know the COVID Vaccine Won’t Have Long-Term Side-Effects?

February 23, 2021

Upcoming Events

Mar 1
Virtual Event
All day

Rare Disease Day at NIH 2021 – Virtual Conference

Mar 2
Virtual Event
March 2 - March 5

Effectiveness of Non-Vaccine Influenza Control Measures

Mar 2
Virtual Event
4:00 pm - 6:00 pm

RNA Viruses: How They Do What They Do

Mar 2
Virtual Event
5:00 pm - 7:00 pm

COVID Seminar Series – Hindsight is 2020

Mar 4
Virtual Event
10:00 am - 1:30 pm

Vulnerabilities in U.S. Chemical Weapons Detection, Identification, and Tracing

View More
Tweets by GlobalBioD

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2021 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Events
    • All Events
    • Deadlines
    • Webinar-Webcast
    • Awareness Events
  • Subscribe

© 2021 Stemar Media Group LLC